TECH OFFERS

Capsule endoscopy is a non-invasive diagnostic method that utilizes a tiny, wireless camera capsule to capture images of the digestive system, which aids in identifying various conditions. Studies indicate that colon cancer is the leading cause of cancer-related deaths among men aged 20-49, and capsule endoscopy is the least invasive examination capable of detecting the early stages of this cancer, alongside other pathologies such as inflammatory bowel disease, ulcers, tumors, and gastro-intestinal bleeding. Without this procedure, these conditions often go undetected and become untreatable by the time noticeable symptoms appear. This technology offer is a remote capsule endoscopy examination, aiming to make colon diagnosis more widespread among people and extend its use to animals, primarily pets like dogs. Regular capsule endoscopy colon screenings are the only way to prevent the growth of undetectable pathologies. Remote technology enables patients to move around or work without needing to stay in a medical facility, allowing diagnoses to be conducted in areas previously unreachable by capsule endoscopy, such as on battlefields, in underdeveloped regions, or even by astronauts in space. The system includes an artificial intelligence module that automatically identifies and suggests potential pathologies in the images to the examining physician. This information assists doctors in quickly navigating through the collection of images, and it can help detect pathologies that may necessitate a more invasive diagnosis or immediate treatment. The technology owner is eager to engage in R&D collaboration with product development partners for gastro-intestinal endoscopic applications for both humans and animals.

Smart Inhalers pose great potential in empowering disease management. Common difficulties faced by patients in the use of inhalers include inaccurate dosing, incorrect inhalation technique, insufficient deep inspiration flow rate and compliance. This technology aims to tackle the issue of over or underdosage delivery, device misuse and lack of monitoring or analytics found in current technologies. Using its proprietary precision dosing system, the device can accurately control dosages with an error rate of as low as 4% while enabling intelligent therapy monitoring and medical reporting for improved patient adherence and treatments. The device functions by breath-activated operation to prevent wastage, heat-free fine particle liquid nebulization for safer drug delivery and deeper lung deposition. It features a propellant-free compact (pocket-sized) smart inhaler with liquid drug cartridges designed to replace injections and modernize inhaled therapies using the lung as a platform for delivery, addressing the lack of pain-free, hassle-free, smart alternatives for various medications. Due to its proprietary atomizer that works on almost 90% of most liquid medication, it has significant potential to be scaled in various drug types and markets, such as insulin, antivirals, hormones, and smart intranasal delivery for neurological conditions.  The technology owner is actively seeking collaboration opportunities with commercialization partners, pharmaceutical, biotech, OEM, CRO companies, who can license it to bring it to market or integrate it into existing healthcare systems. This scalability makes the technology highly appealing to a wide range of potential partners and licensees including co-development for customization and R&D or joint venture.  

Pressure sensitive adhesives (PSAs) are viscous resins that are designed to adhere to various substrates under light pressure. Majority of commercially available PSAs are derived from non-renewable petroleum sources such as acrylics and silicones, providing the required bonding performance for either permanent or removable applications for use in labels and packaging. However, conventional PSAs present environmental concerns at their end of life, even when its substrate is biodegradable. The technology on offer is a patented bio-based, compostable PSAs comprising of 95% soy and other bio-derived materials that costs less than petroleum adhesives. These PSAs can bond to a variety of substrates (including paper and foams), contains no solvent or water, lowers CO2 emissions when compared to conventional PSA. It can be applied using standard application techniques (slot die or gravure systems) and upon curing will result in a light, cream coloured film. The technology owner is seeking for R&D collaborations and IP licensing opportunities with Singapore partners to manufacture/utilise the technology in packaging and non-structural applications.

Asia accounts for approximately 70% of the world’s seafood consumption, around 69.6 million metric tons. This is more than twice the total amount consumed by the rest of the world.* Commercially, about 30% of the seafood is not consumed, from bones to offals, to skin/shell/scales. These food loss and waste potentially impose environmental and socioeconomic issues.  The technology provider has developed a green chemical process converting seafood sidestreams into food products that are not only high value but also nutritious, addressing Singapore’s demand to increase production of nutrient dense foods. In addition, this method is efficient and cost effective as it requires basic equipment. The technology provider is looking for R&D collaborators and for test-bedding especially with industries who are producing aquaculture food with high nutritional value and interested to utilise their sidestreams more sustainably. * FAO 2018

In recent years, carbon dioxide (CO2) levels in the atmosphere have reached unacceptably high levels. The CO2 in the air can be captured but a method of effectively utilising or sequestrating it remains to be found. Therefore, there is a need for a new technology that can cost effectively, and energy efficiently utilise or sequestrate CO2. This technology offer uses a natural, low-temperature, liquid-phase processes to electrochemically convert captured CO2 into syngas, a mixture of hydrogen (H2) and carbon monoxide (CO). This is highly desired as syngas is the precursor of many useful materials such as plastics, ammonia, methane and methanol and is typically made from fossil fuel.  Any emitters of CO2 could integrate this technology into their plants to both reduce their carbon emissions and increase overall system efficiency.  The projected costs show that the syngas will be able to compete with fossil sources based on price, in many cases, without the need for a carbon subsidy or relying on any value from the oxygen (O2) produced as a co-product. The technology owner is looking for partners in various CO2 emitting industries for further co-development and test bedding of the solution. The technology owner is also keen to license this technology as well.

The conventional DC brushless motors face the challenge of reduced output when their size is reduced to achieve a smaller product, as well as the difficulty of precise control according to the load. A unique solution to these problems would be the use of compact, high-power DC brushless motors with vector control technology. These current issues contributed to the product developers in the creation of more compact and lightweight products that offer improved performance and increased functionality by responding to load-specific characteristics. With vector control technology, these motors provide precise control over motor speed and torque, resulting in enhanced efficiency and reduced energy consumption. The benefits of using these motors include improved product design, increased functionality, and greater efficiency The technology offer comprises of two portions of the motor internal structural design and the use of vector control technology to maximize the performance of the overall system.  These unique motors control system offers a reliable and effective solution to the challenges faced by conventional DC brushless motors. The technology owner is keen to do R&D collaboration and licensing out the know-how to a variety of applications such as robotics, electric vehicles, and industrial automation systems.   

Medical 3D printing is expected to grow in the coming years due to the rising demand for patient-specific surgery products and medical devices. The use of 3D printing in healthcare sectors also enables benefits such as shorter time, lower costs, and faster healing of patients. The most affordable and popular method that domain the medical 3D printing is fused deposition modelling (FDM). However, the current medical grade 3D printing materials have limitations. For example, the commonly used PEEK filament has no bioactivity and may cause bone-polymer interface issues during long-term applications. Using unique formulation and advanced nanotechnology, the technology owner has developed a new kind of FDM printing filament, that has excellent bioactivity and is suitable for long-term implantation. It is a PMMA based co-polymer with the addition of nano-hydroxyapatite coated crystal fillers to increase the bioactivity. It shares similar mechanical properties to natural bone and is adhesive to bone cells, leading to better efficacy. This technology is available for collaborations with partners in medical and healthcare sectors, e.g., biotech companies, medical device manufactures, hospitals and surgical centres, dental clinics, research institutes and laboratories, etc.

Partial discharges (PDs) are early indicators of the deteriorating health condition of high-voltage electrical assets in power distribution networks. PDs are caused by localised dielectric breakdowns within assets such as generators, transformers, and switchgears. Left undetected, the health of the assets can deteriorate and lead to irreversible damage, posing safety hazards such as fire and explosion. Therefore, there is a need to detect and monitor PD events to ensure asset health and safety to extend the life time.  This technology offer is a compact PD sensor equipped with a fast detector which can be mounted on assets to detect and monitor PD events 24/7. The system integrates a wireless platform, allowing remote retrieval of information about the times of PD occurrences and source identifications (IDs). This information can be used to trace and identify PD emitting sources. By using the proposed technology to detect and monitor PD events, early signs of asset degradation can be identified. This allows necessary preventive measures to be taken to avoid unexpected failures and damages, saving costs associated with repair or replacement. Additionally, the technology enhances safety by minimizing the risk of fire and explosion caused by PD-related damages. Overall, the proposed technology helps ensure the health and safety of high-voltage electrical assets, while reducing costs and downtime associated with unexpected failures and damages. The technology owner is keen to do R&D collaboration and licensing to high-voltage equipment manufacturers, and power system maintenance service providers.

When planning surgeries, doctors and medical engineers need to create 3D surgical plans pre-operation, and their only way to model internal body parts is to rely on Computerized Tomography (CT) images. For patients living with implanted metal artifacts, the artifacts will lead to an interference on image generation and visualization of anatomical structures thereby resulting in visual errors of the images. Current available CT image generating tools has its limitations in processing images with visual noise such that it greatly reduces the visibility of hard and soft bone surfaces. This leaves medical engineers with an extended period of manual image correction and uncertainty, resulting in higher risk of unsuccessful surgeries due to inaccurate surgical modelling. The process of bone segmentation usually takes several hours as Cone Beam Computed Tomography (CBCTs) need to be corrected manually.  To overcome these challenges, the company has developed an algorithm to create automated 3D models that is cost-efficient and timely. The technology is able to deliver precise anatomical identity of both hard and soft bone surface and is compatible with all segmentation and planner software. This technology is clinically proven for Maxillofacial and Orthodontics 3D surgical planning (bone grafting and implantation) and can be integrated into systems of CBCT machine and Medical 3D printer.